表紙
市場調查報告書
商品編碼
975015

類風濕關節炎的全球市場:藥物種類,給藥途徑和銷售渠道的市場機會分析和行業預測(2020-2027)

Rheumatoid Arthritis Drugs Market by Drug Class, Route of Administration, and Sales Channel : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日期: | 出版商: Allied Market Research | 英文 219 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2019年,類風濕關節炎的全球市場價值為579.29億美元,從2020年到2027年的複合年增長率為2.8%,到2027年將有望達到629.35億美元。

類風濕關節炎是一種自身免疫性疾病,主要影響關節以及關節組織和關節外器官。它被認為是系統性疾病,因為它會影響心臟和呼吸系統。該病也常常是進行性的,導致關節僵硬,疼痛,發紅和腫脹。另外,對於風濕性關節炎還沒有永久性的治療方法,因此治療的目標是減輕疼痛,預防骨骼畸形,減輕炎症並改善患者全身的機能。這可以通過改變疾病的抗風濕藥(DMARD),非甾體抗炎藥(NSAID),皮質類固醇和尿酸藥來實現。但是,早期診斷和治療對於更好地治療類風濕關節炎很重要。

類風濕關節炎的發病率急劇上升,對DMARDs的需求增加以及全球老年人口的迅速增加是推動全球類風濕關節炎藥物市場增長的關鍵因素。此外,越來越多的患者意識到類風濕性關節炎的各種治療方法的可利用性,製藥公司對罕見病和特殊疾病領域的開拓越來越引起人們的關注,尤其是在世界範圍內,越來越多的研發活動和產品創新。它有助於市場的增長。此外,可用於治療類風濕性關節炎的生物仿製藥的最新進展以及越來越多的法規批准正在推動市場增長。但是,與藥物治療相關的副作用和生物DMARD治療的高成本預計會阻礙全球市場的增長。

本報告調查了全球類風濕關節炎藥物市場,並按藥物類別,給藥途徑,銷售渠道和地區,市場趨勢,增長促進因素和抑制因素,概述了市場,市場規模的趨勢和預測。它提供全面的信息,例如分析,市場機會,競爭狀況和主要公司的概況。

目錄

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資口袋
  • 主要公司的定位,2019年
  • 波特的五力分析
  • 市場動態
    • 生長因素
      • 世界老齡人口迅速增加
      • 全球醫療費用增加
      • 世界範圍內類風濕關節炎的患病率上升
    • 抑制因素
      • 發展中國家缺乏治療類風濕關節炎的機會
    • 市場機會
      • 新興市場的高增長潛力
    • 影響分析
  • 分析Covid-19對類風濕關節炎藥物市場的影響

第4章類風濕性關節炎藥品市場:按藥品類別

  • 概述
    • 市場規模和預測
  • 祛病抗風濕藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 非甾體抗炎藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測
    • 市場分析:按國家
  • 皮質類固醇
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測
    • 市場分析:按國家
  • 尿酸藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測
    • 市場分析:按國家
  • 其他
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測
    • 市場分析:按國家

第5章類風濕關節炎治療市場:按管理途徑

  • 概述
    • 市場規模和預測
  • 口頭
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 腸胃外
    • 市場規模和預測:按地區
    • 市場分析:按國家

第6章類風濕關節炎藥品市場:按銷售渠道

  • 概述
    • 市場規模和預測
  • 處方藥
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 非處方藥
    • 市場規模和預測:按地區
    • 市場分析:按國家

第7章類風濕關節炎藥物市場:按地區

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
      • 美國
      • 加拿大
      • 墨西哥
    • 北美市場規模和預測:按藥品類別
    • 北美市場規模和預測:按管理途徑劃分
    • 北美市場規模和預測:按銷售渠道劃分
  • 歐洲
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
    • 歐洲市場規模和預測:按藥品類別
    • 歐洲市場規模和預測:按管理途徑劃分
    • 歐洲市場規模和預測:按銷售渠道劃分
  • 亞太地區
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
    • 亞太市場規模和預測:按藥品類別
    • 亞太市場規模和預測:按管理路線劃分
    • 亞太市場規模和預測:按銷售渠道劃分
  • 拉美
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他LAMEA
    • LAMEA市場規模和預測:按藥品類別
    • LAMEA市場規模和預測:按管理途徑劃分
    • LAMEA市場規模和預測:按銷售渠道劃分

第8章公司簡介

  • ABBVIE INC.
  • AMGEN INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS AG (SANDOZ)
  • PFIZER INC.
  • UCB S.A.
目錄
Product Code: A03411

Title:
Rheumatoid Arthritis Drugs Market by Drug Class (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others), Route of Administration (Oral and Parenteral), and Sales Channel (Prescription-based Drugs, and Over-the-counter Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global rheumatoid arthritis drugs market was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027.

Rheumatoid arthritis is an autoimmune disease that majorly affects joints along with articular tissues and extra-articular organs. It is considered as a systemic disease, as it affects the cardiac and respiratory system. In addition, this medical condition is often progressive, and results in stiffness, pain, redness, and swelling of joints. Moreover, as no permanent cure is available for rheumatoid arthritis, the aim of the treatment is to reduce pain, prevent bone deformity, decrease inflammation, and improve a person's overall body function. This is achieved through disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs. However, early diagnosis and treatment are the key for better management of the rheumatoid arthritis.

Alarming rise in incidence of rheumatoid arthritis, increase in demand for DMARDs, and surge in geriatric population across the globe are the key factors that fuel the growth of the global rheumatoid arthritis drugs market. In addition, rise in patient awareness toward availability of various treatments for rheumatoid arthritis, increase in focus of pharmaceutical companies to tap the rare & specialty diseases, and rise in R&D activities and product innovations notably contribute toward the growth of the global market. Moreover, recent advancements in biosimilars, which may be used to treat rheumatoid arthritis and rise in approvals of the same by regulatory authorities drive the growth of the market. However, side effects associated with the medication and high costs of biological DMARD therapies are expected to hinder the growth of the market, globally.

The global rheumatoid arthritis drugs market is segmented into drug class, route of administration, sales channel, and region. Depending on drug class, the market is categorized into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. By route of administration, it is segregated into oral and parenteral. On the basis of sales channel, it is fragmented into prescription-based drugs and over-the-counter drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Class

  • Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Sales Channel

  • Prescription-based Drugs
  • Over-the-counter Drugs

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Biogen Inc
  • Takeda Pharmaceutical Company
  • Swedish Orphan Biovitrum AB (SOBI)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective44

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Top player positioning, 2019
  • 3.4.Porter's five force analysis
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Surge in geriatric population across the globe
      • 3.5.1.2.Increase in healthcare expenditure worldwide
      • 3.5.1.3.Rise in prevalence of rheumatoid arthritis across the globe
    • 3.5.2.Restraint
      • 3.5.2.1.Lack of access to treatment of rheumatoid arthritis in underdeveloped countries
    • 3.5.3.Opportunity
      • 3.5.3.1.High growth potential in emerging markets
    • 3.5.4.Impact analysis
  • 3.6.Covid-19 impact analysis on rheumatoid arthritis drugs market

CHAPTER 4:RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Disease-modifying anti-rheumatic drugs
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Nonsteroidal anti-inflammatory drugs
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Corticosteroids
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country
  • 4.5.Uric acid drugs
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast
    • 4.5.3.Market analysis, by country
  • 4.6.Others
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast
    • 4.6.3.Market analysis, by country

CHAPTER 5:RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Oral
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Parenteral
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Prescription-based drugs
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Over-the-counter drugs
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country

CHAPTER 7:RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. rheumatoid arthritis drugs market, by drug class
      • 7.2.2.1.2.U.S. rheumatoid arthritis drugs market, by route of administration
      • 7.2.2.1.3.U.S. rheumatoid arthritis drugs market, by sales channel
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada rheumatoid arthritis drugs market, by drug class
      • 7.2.2.2.2.Canada rheumatoid arthritis drugs market, by route of administration
      • 7.2.2.2.3.Canada rheumatoid arthritis drugs market, by sales channel
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico rheumatoid arthritis drugs market, by drug class
      • 7.2.2.3.2.Mexico rheumatoid arthritis drugs market, by route of administration
      • 7.2.2.3.3.Mexico rheumatoid arthritis drugs market, by sales channel
    • 7.2.3.North America market size and forecast, by drug class
    • 7.2.4.North America market size and forecast, by route of administration
    • 7.2.5.North America market size and forecast, by sales channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany rheumatoid arthritis drugs market, by drug class
      • 7.3.2.1.2.Germany rheumatoid arthritis drugs market, by route of administration
      • 7.3.2.1.3.Germany rheumatoid arthritis drugs market, by sales channel
      • 7.3.2.2.France
      • 7.3.2.2.1.France rheumatoid arthritis drugs market, by drug class
      • 7.3.2.2.2.France rheumatoid arthritis drugs market, by route of administration
      • 7.3.2.2.3.France rheumatoid arthritis drugs market, by sales channel
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK rheumatoid arthritis drugs market, by drug class
      • 7.3.2.3.2.UK rheumatoid arthritis drugs market, by route of administration
      • 7.3.2.3.3.UK rheumatoid arthritis drugs market, by sales channel
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy rheumatoid arthritis drugs market, by drug class
      • 7.3.2.4.2.Italy rheumatoid arthritis drugs market, by route of administration
      • 7.3.2.4.3.Italy rheumatoid arthritis drugs market, by sales channel
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain rheumatoid arthritis drugs market, by drug class
      • 7.3.2.5.2.Spain rheumatoid arthritis drugs market, by route of administration
      • 7.3.2.5.3.Spain rheumatoid arthritis drugs market, by sales channel
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe rheumatoid arthritis drugs market, by drug class
      • 7.3.2.6.2.Rest of Europe rheumatoid arthritis drugs market, by route of administration
      • 7.3.2.6.3.Rest of Europe rheumatoid arthritis drugs market, by sales channel
    • 7.3.3.Europe market size and forecast, by drug class
    • 7.3.4.Europe market size and forecast, by route of administration
    • 7.3.5.Europe market size and forecast, by sales channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan
      • 7.4.2.1.1.Japan rheumatoid arthritis drugs market, by drug class
      • 7.4.2.1.2.Japan rheumatoid arthritis drugs market, by route of administration
      • 7.4.2.1.3.Japan rheumatoid arthritis drugs market, by sales channel
      • 7.4.2.2.China
      • 7.4.2.2.1.China rheumatoid arthritis drugs market, by drug class
      • 7.4.2.2.2.China rheumatoid arthritis drugs market, by route of administration
      • 7.4.2.2.3.China rheumatoid arthritis drugs market, by sales channel
      • 7.4.2.3.Australia
      • 7.4.2.3.1.Australia rheumatoid arthritis drugs market, by drug class
      • 7.4.2.3.2.Australia rheumatoid arthritis drugs market, by route of administration
      • 7.4.2.3.3.Australia rheumatoid arthritis drugs market, by sales channel
      • 7.4.2.4.India
      • 7.4.2.4.1.India rheumatoid arthritis drugs market, by drug class
      • 7.4.2.4.2.India rheumatoid arthritis drugs market, by route of administration
      • 7.4.2.4.3.India rheumatoid arthritis drugs market, by sales channel
      • 7.4.2.5.South Korea
      • 7.4.2.5.1.South Korea rheumatoid arthritis drugs market, by drug class
      • 7.4.2.5.2.South Korea rheumatoid arthritis drugs market, by route of administration
      • 7.4.2.5.3.South Korea rheumatoid arthritis drugs market, by sales channel
      • 7.4.2.6.Rest of Asia-Pacific
      • 7.4.2.6.1.Rest of Asia-Pacific rheumatoid arthritis drugs market, by drug class
      • 7.4.2.6.2.Rest of Asia-Pacific rheumatoid arthritis drugs market, by route of administration
      • 7.4.2.6.3.Rest of Asia-Pacific rheumatoid arthritis drugs market, by sales channel
    • 7.4.3.Asia-Pacific market size and forecast, by drug class
    • 7.4.4.Asia-Pacific market size and forecast, by route of administration
    • 7.4.5.Asia-Pacific market size and forecast, by sales channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
      • 7.5.2.1.Brazil
      • 7.5.2.1.1.Brazil rheumatoid arthritis drugs market, by drug class161
      • 7.5.2.1.2.Brazil rheumatoid arthritis drugs market, by route of administration
      • 7.5.2.1.3.Brazil rheumatoid arthritis drugs market, by sales channel
      • 7.5.2.2.Saudi Arabia
      • 7.5.2.2.1.Saudi Arabia rheumatoid arthritis drugs market, by drug class
      • 7.5.2.2.2.Saudi Arabia rheumatoid arthritis drugs market, by route of administration
      • 7.5.2.2.3.Saudi Arabia rheumatoid arthritis drugs market, by sales channel
      • 7.5.2.3.South Africa
      • 7.5.2.3.1.South Africa rheumatoid arthritis drugs market, by drug class
      • 7.5.2.3.2.South Africa rheumatoid arthritis drugs market, by route of administration
      • 7.5.2.3.3.South Africa rheumatoid arthritis drugs market, by sales channel
      • 7.5.2.4.Rest of LAMEA
      • 7.5.2.4.1.Rest of LAMEA rheumatoid arthritis drugs market, by drug class
      • 7.5.2.4.2.Rest of LAMEA rheumatoid arthritis drugs market, by route of administration
      • 7.5.2.4.3.Rest of LAMEA rheumatoid arthritis drugs market, by sales channel
    • 7.5.3.LAMEA market size and forecast, by drug class
    • 7.5.4.LAMEA market size and forecast, by route of administration
    • 7.5.5.LAMEA market size and forecast, by sales channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABBVIE INC.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.AMGEN INC.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.BRISTOL-MYERS SQUIBB COMPANY
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.ELI LILLY AND COMPANY
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.F. HOFFMANN-LA ROCHE LTD.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.JOHNSON & JOHNSON
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.MERCK & CO., INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.NOVARTIS AG (SANDOZ)
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.PFIZER INC.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.UCB S.A.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
    • 8.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 02.DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.CORTICOSTEROIDS RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.URIC ACID RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 06.OTHERS RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 ($MILLION)
  • TABLE 08.ORAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.PARENTERAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027 ($MILLION)
  • TABLE 11.PRESCRIPTION-BASED RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.OVER-THE-COUNTER RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.RHEUMATOID ARTHRITIS DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 15.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 16.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 17.U.S. RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 18.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 19.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 20.CANADA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 21.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 22.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 23.MEXICO RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 24.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 25.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 26.NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 27.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 28.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 29.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 30.GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 31.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 32.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 33.FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 34.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 35.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 36.UK RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 37.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 38.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 39.ITALY RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 40.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 41.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 42.SPAIN RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 43.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 44.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 45.REST OF EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 46.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 47.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 48.EUROPE RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 49.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 50.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 51.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 52.JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 53.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 54.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 55.CHINA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 56.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 57.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 58.AUSTRALIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 59.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 60.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 61.INDIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 62.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 63.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 64.SOUTH KOREA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 65.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 66.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 67.REST OF ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 68.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 69.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 70.ASIA-PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 71.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 72.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 73.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 74.BRAZIL RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 75.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 76.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 77.SAUDI ARABIA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 78.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 79.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 80.SOUTH AFRICA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 81.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 82.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 83.REST OF LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 84.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY DRUG CLASS, 2019-2027
  • TABLE 85.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027
  • TABLE 86.LAMEA RHEUMATOID ARTHRITIS DRUGS MARKET, BY SALES CHANNEL, 2019-2027
  • TABLE 87.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 88.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 89.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90.AMGEN: COMPANY SNAPSHOT
  • TABLE 91.AMGEN: PRODUCT PORTFOLIO
  • TABLE 92.BMS: COMPANY SNAPSHOT
  • TABLE 93.BMS: PRODUCT PORTFOLIO
  • TABLE 94.LILLY: COMPANY SNAPSHOT
  • TABLE 95.LILLY: PRODUCT PORTFOLIO
  • TABLE 96.LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97.ROCHE: COMPANY SNAPSHOT
  • TABLE 98.ROCHE: OPERATING SEGMENT
  • TABLE 99.ROCHE: PRODUCT PORTFOLIO
  • TABLE 100.J&J: COMPANY SNAPSHOT
  • TABLE 101.J&J: OPERATING SEGMENTS
  • TABLE 102.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 103.MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 104.MERCK & CO., INC.: OPERATING SEGMENTS
  • TABLE 105.MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 106.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 108.NOVARTIS: OPERATING SEGMENT
  • TABLE 109.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 110.PFIZER: COMPANY SNAPSHOT
  • TABLE 111.PFIZER: OPERATING SEGMENT
  • TABLE 112.PFIZER: PRODUCT PORTFOLIO
  • TABLE 113.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114.UCB: COMPANY SNAPSHOT
  • TABLE 115.UCB: OPERATING SEGMENT
  • TABLE 116.UCB: PRODUCT PORTFOLIO
  • TABLE 117.UCB: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP PLAYER POSITIONING, 2019
  • FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06.HIGH THREAT OF SUBSTITUTES
  • FIGURE 07.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08.MODERATE INTENSITY OF RIVALRY
  • FIGURE 09.IMPACT ANALYSIS
  • FIGURE 10.COMPARATIVE ANALYSIS OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 11.COMPARATIVE ANALYSIS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF CORTICOSTEROIDS RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 13.COMPARATIVE ANALYSIS OF URIC ACID RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF OTHER RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF ORAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF PARENTERAL RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF PRESCRIPTION-BASED RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER RHEUMATOID ARTHRITIS DRUGS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 19.ABBVIE INC: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 20.ABBVIE INC.: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 21.AMGEN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 22.AMGEN: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 23.BMS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 24.BMS: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 25.LILLY: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 26.LILLY: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 27.ROCHE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 28.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 29.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 30.J&J: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 31.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 32.J&J: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 33.MERCK & CO., INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 34.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 35.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 36.NOVARTIS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 37.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 38.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 39.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 40.PFIZER: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 41.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 42.UCB: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 43.UCB: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 44.UCB: REVENUE SHARE BY REGION, 2019 (%)